The Children's Hospital of Philadelphia has selected Advancing Craniofacial Treatment with Genomics and Gene Therapy (ACTG) as a FY25 Frontier Program. Led by Eric C. Liao, PhD, MD; Jesse Taylor, MD; and William Peranteau, MD, ACTG will harness the power of genomic medicine to develop precision treatment plans and predict outcomes for children with craniofacial conditions. The program will also spearhead innovations in gene therapy, with the goal of developing novel treatment options for children with cleft and craniofacial conditions. Alongside Drs. Liao, Taylor, and Peranteau, the research collaboration team also includes Kai Wang, PhD; Mohamad-Gabriel Alameh, PhD; and Justin Cotney, PhD.
Comments